Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert

Vaccine

Volumn 24, Issue 4, 2006, Pages 532-539

  Kim, H Nina ^a   Tabet, Stephen R ^a   Corey, Lawrence ^a,b   Celum, Connie L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Acute HIV 1 infection; Antiretroviral therapy; HIV 1 vaccine trials

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SCREENING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; INFECTION PREVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SEROCONVERSION; VIRUS LOAD; VIRUS TRANSMISSION;

AIDS VACCINES; ANTI-HIV AGENTS; ANTIBODIES, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 29244434983     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.05.049     Document Type: Article

References (59)

1. J. Cohen HIV/AIDS. Prevention cocktails: combining tools to stop HIV's spread Science 309 5737 2005 1002 1005
2. T.C. Quinn, M.J. Wawer, and N. Sewankambo Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group N Engl J Med 342 13 2000 921 929
3. S. Blower, E.J. Schwartz, and J. Mills Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines AIDS Rev 5 2 2003 113 125
4. D. Lee, B.S. Graham, and Y.-L. Chiu Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160 J Infect Dis 190 5 2004 903 907
5. D.W. Fitzgerald, J.W. Pape, J.N. Wasserheit, G.W. Counts, and L. Corey Provision of treatment in HIV-1 vaccine trials in developing countries Lancet 362 9388 2003 993 994
6. R. Bayer Ethical challenges of HIV vaccine trials in less developed nations: conflict and consensus in the international arena AIDS 14 8 2000 1051 1057
7. UNAIDS/WHO. Ethical considerations in HIV preventive vaccine research. UNAIDS (Joint United Nations Programme on HIV/AIDS). Geneva, Switzerland; 2000.
8. T.W. Schacker, J.P. Hughes, T. Shea, R.W. Coombs, and L. Corey Biological and virologic characteristics of primary HIV infection Ann Intern Med 128 8 1998 613 620
9. R.H. Lyles, A. Munoz, and T.E. Yamashita Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study J Infect Dis 181 3 2000 872 880
10. J.W. Mellors, C.R. Rinaldo Jr., P. Gupta, R.M. White, J.A. Todd, and L.A. Kingsley Prognosis in HIV-1 infection predicted by the quantity of virus in plasma Science 272 5265 1996 1167 1170
11. R.H. Gray, M.J. Wawer, and R. Brookmeyer Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda Lancet 357 9263 2001 1149 1153
12. P.B. Gilbert, V.G. DeGruttola, M.G. Hudgens, S.G. Self, S.M. Hammer, and L. Corey What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials J Infect Dis 188 2 2003 179 193
13. D.H. Barouch, J. Kunstman, and M.J. Kuroda Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes Nature 415 6869 2002 335 339
14. P.J. Goulder, R.E. Phillips, and R.A. Colbert Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS Nat Med 3 2 1997 212 217
15. J.M. Pincus, S.S. Crosby, E. Losina, E.R. King, C. LaBelle, and K.A. Freedberg Acute human immunodeficiency virus infection in patients presenting to an urban urgent care center Clin Infect Dis 37 12 2003 1699 1704
16. A.M. Kuo, J.S. Haukoos, M.D. Witt, M.L. Babaie, and R.J. Lewis Recognition of undiagnosed HIV infection: an evaluation of missed opportunities in a predominantly urban minority population AIDS Patient Care and STDs 19 4 2005 239 246
17. C.L. Celum, S.P. Buchbinder, and D. Donnell Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load J Infect Dis 183 1 2001 23 35
18. M. Schechter Therapy for early HIV infection: how far back should the pendulum swing? J Infect Dis 190 6 2004 1043 1045
19. D.D. Ho Time to hit HIV, early and hard N Engl J Med 333 7 1995 450 451
20. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, April 7, 2005. Department of Health & Human Services; 2005.
21. J.O. Kahn, and B.D. Walker Acute human immunodeficiency virus type 1 infection N Engl J Med 339 1 1998 33 39
22. G.R. Kaufmann, J.J. Zaunders, and P. Cunningham Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection AIDS 14 17 2000 2643 2651
23. U. Malhotra, M.M. Berrey, and Y. Huang Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection J Infect Dis 181 1 2000 121 131
24. J.J. Zaunders, P.H. Cunningham, and A.D. Kelleher Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia J Infect Dis 180 2 1999 320 329
25. G.M. Ortiz, J. Hu, and J.A. Goldwitz Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection J Virol 76 1 2002 411 415
26. R. Shankarappa, J.B. Margolick, and S.J. Gange Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection J Virol 73 12 1999 10489 10502
27. M. Sagar, L. Lavreys, and J.M. Baeten Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression J Virol 77 23 2003 12921 12926
28. J.S. Koopman, J.A. Jacquez, and G.W. Welch The role of early HIV infection in the spread of HIV through populations J Acquir Immune Defic Syndr Hum Retrovirol 14 3 1997 249 258
29. C.D. Pilcher, H.C. Tien, and J.J. Eron Jr. Brief but efficient: acute HIV infection and the sexual transmission of HIV J Infect Dis 189 10 2004 1785 1792
30. M.J. Wawer, R.H. Gray, and N.K. Sewankambo Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda J Infect Dis 191 9 2005 1403 1409
31. S.U. Sankatsing, R.M. van Praag, and R.P. van Rij Dynamics of the pool of infected resting CD4 HLA-DR-T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection Antivir Ther 8 2 2003 137 142
32. T.W. Chun, D. Engel, M.M. Berrey, T. Shea, L. Corey, and A.S. Fauci Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection Proc Natl Acad Sci USA 95 15 1998 8869 8873
33. T. Schacker, S. Little, and E. Connick Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy J Infect Dis 181 1 2000 354 357
34. Q. Li, L. Duan, and J.D. Estes Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells Nature 434 7037 2005 1148 1152
35. J.J. Mattapallil, D.C. Douek, B. Hill, Y. Nishimura, M. Martin, and M. Roederer Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection Nature 434 7037 2005 1093 1097
36. S. Mehandru, M.A. Poles, and K. Tenner-Racz Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract J Exp Med 200 6 2004 761 770
37. D.E. Kaufmann, M. Lichterfeld, and M. Altfeld Limited durability of viral control following treated acute HIV infection PLoS Med 1 2 2004 e36
38. D.E. Smith, B.D. Walker, D.A. Cooper, E.S. Rosenberg, and J.M. Kaldor Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS 18 5 2004 709 718
39. M.M. Berrey, T.W. Schacker, and A.C. Collier Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to aids J Infect Dis 183 10 2001 1466 1475
40. B. Hoen, B. Dumon, and M. Harzic Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial J Infect Dis 180 4 1999 1342 1346
41. D. Smith, M.M. Berrey, and M. Robertson Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection J Infect Dis 182 3 2000 950 954
42. S. Yerly, L. Kaiser, and T.V. Perneger Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study AIDS 14 3 2000 243 249
43. M. Markowitz, M. Vesanen, and K. Tenner-Racz The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses J Infect Dis 179 3 1999 527 537 [erratum: J Infect Dis 1999;1179:1315]
44. F.B. Lillo, D. Ciuffreda, and F. Veglia Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection AIDS 13 7 1999 791 796
45. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. Geneva: World Health Organization; 2004.
46. T.R. Sterling, R.E. Chaisson, and R.D. Moore HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy AIDS 15 17 2001 2251 2257
47. R.S. Hogg, B. Yip, and K.J. Chan Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy JAMA 286 20 2001 2568 2577
48. M. Egger, M. May, and G. Chene Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies Lancet 360 9327 2002 119 129
49. J.E. Kaplan, D.L. Hanson, and D.L. Cohn When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/μL Clin Infect Dis 37 7 2003 951 958
50. A.N. Phillips, S. Staszewski, and R. Weber HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load JAMA 286 20 2001 2560 2567
51. E. Wood, R.S. Hogg, B. Yip, P.R. Harrigan, M.V. O'Shaughnessy, and J.S. Montaner Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS 17 5 2003 711 720
52. J.W. Mellors, A. Munoz, and J.V. Giorgi Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection Ann Intern Med 126 12 1997 946 954
53. G. Skowron, J.C. Street, and E.M. Obee Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy J Acquir Immune Defic Syndr 28 4 2001 313 319
54. T.F. Rinke de Wit, A. Tsegaye, and D. Wolday Primary HIV-1 subtype C infection in Ethiopia J Acquir Immune Defic Syndr 30 5 2002 463 470
55. A.D. Sarr, G. Eisen, and A. Gueye-Ndiaye Viral dynamics of primary HIV-1 infection in Senegal, West Africa J Infect Dis 191 9 2005 1460 1467
56. -1 AIDS 16 10 2002 1371 1381
57. 3: disease progression, treatment durability, and drug toxicity Clin Infect Dis 36 6 2003 812 815
58. E. Wood, R.S. Hogg, B. Yip, P.R. Harrigan, M.V. O'Shaughnessy, and J.S. Montaner Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 × 10(9)-0.350 × 10(9) cells/L Ann Intern Med 139 10 2003 810 816
59. R.M. Gulick, H.J. Ribaudo, and C.M. Shikuma Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection N Engl J Med 350 18 2004 1850 1861